Keywords: EMA, ARBs, Hypertension, Advagrad, Protelos, Astellas, Servier, Immunosuppresant, Osteoarthritis

EMA says risk-benefit of ARBs positive; acts on Advagraf and Protelos/Osseor

Article | 21 October 2011

Print This

In a flurry of late news yesterday from the European Medicines Agency and its Committee for Medicinal Products for Human ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in